Innovative Cancer Treatment RefleXion Medical's FDA-cleared SCINTIX biology-guided radiotherapy system represents a significant technological advancement in targeted cancer treatment, offering potential expansion opportunities into oncology centers seeking cutting-edge solutions.
Strong Funding Support With a recent $105 million investment led by The Rise Fund and TPG, RefleXion has substantial financial backing, enabling growth, product development, and market penetration efforts, making it a promising partner for health systems investing in advanced oncology technologies.
Strategic Partnerships Recent collaborations with 3B Pharmaceuticals for radiopharmaceutical rights and a new product launch at prominent industry events suggest opportunities to co-develop integrated treatment options and expand into multi-modality cancer care.
Market Expansion Potential RefleXion’s recent product launch and ongoing clinical developments position it to tap into the growing demand for biology-guided radiotherapy, especially within large hospital networks and cancer treatment centers looking for innovative, minimally invasive solutions.
Competitive Landscape While facing legal challenges from Salem Health, RefleXion’s innovative technology and notable funding differentiate it from competitors like Accuray and Elekta, presenting opportunities to target hospitals and clinics seeking next-generation cancer treatment platforms.
RefleXion Medical uses 8 technology products and services including AutoCAD, Salesforce Field Service Lightning, Font Awesome, and more. Explore RefleXion Medical's tech stack below.
| RefleXion Medical Email Formats | Percentage |
| FLast@reflexionmedical.com | 80% |
| First@reflexionmedical.com | 9% |
| First.Last@reflexionmedical.com | 5% |
| FirstLast@reflexionmedical.com | 3% |
| Last@reflexionmedical.com | 2% |
| FMiddleLast@reflexionmedical.com | 1% |
| FLast@reflexion.com | 75% |
| Last@reflexion.com | 15% |
| First@reflexion.com | 7% |
| First.Last@reflexion.com | 3% |
Medical Equipment ManufacturingUnited States201-500 Employees
SCINTIX biology-guided radiotherapy now FDA cleared. SCINTIX® therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
Company Overview
Media & News
Funding & FinancialsRefleXion Medical has raised a total of $105M of funding over 11 rounds. Their latest funding round was raised on Nov 15, 2023 in the amount of $105M.
RefleXion Medical's revenue is estimated to be in the range of $50M$100M
Funding & FinancialsRefleXion Medical has raised a total of $105M of funding over 11 rounds. Their latest funding round was raised on Nov 15, 2023 in the amount of $105M.
RefleXion Medical's revenue is estimated to be in the range of $50M$100M
1-888-653-2347 
support@leadiq.com